Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

0.0%

0 terminated/withdrawn out of 12 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

25%

3 trials in Phase 3/4

Results Transparency

0%

0 of 1 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 3
3(60.0%)
N/A
2(40.0%)
5Total
Phase 3(3)
N/A(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (12)

Showing 12 of 12 trials
NCT07565623Not ApplicableNot Yet Recruiting

Prevention of AIDS With Opportunistic Infection Paradoxical IRIS

Role: collaborator

NCT07240753Not Yet Recruiting

A Chinese Cohort of Cervical Large Cell Neuroendocrine Carcinoma

Role: collaborator

NCT06685458Not Yet Recruiting

Constructing a Predictive Model for Differentiating Between Benign and Malignant Solid Pulmonary Nodules Based on Clinical and Imaging Features.

Role: lead

NCT06645743Not Yet Recruiting

Retrospective Analysis of Clinical and CT Features to Predict Spread Through Air Space in Stage IA Lung Adenocarcinoma

Role: lead

NCT02288195Phase 3Unknown

CONVERT: Neoadjuvant Chemotherapy Alone Versus Preoperative Chemoradiation for Locally Advanced Rectal Cancer Patients

Role: collaborator

NCT04278274Unknown

Post-Neoadjuvant Treatment MRI Based AI System to Predict pCR for Rectal Cancer

Role: collaborator

NCT04271657Completed

RadioPathomics Artificial Intelligence Model to Predict nCRT Response in Locally Advanced Rectal Cancer

Role: collaborator

NCT04711434Phase 3Unknown

PD-1 Antibody for The Prevention of Adenomatous Polyps and Second Primary Tumors in Lynch Syndrome Patients

Role: collaborator

NCT04273451Unknown

RadioPathomics Artificial Intelligence Model to Predict Tumor Regression Grading in Locally Advanced Rectal Cancer

Role: collaborator

NCT04273477Unknown

Radiomics-based Artificial Intelligence System to Predict Neoadjuvant Treatment Response in Rectal Cancer

Role: collaborator

NCT03351062Phase 3Unknown

Efficacy of Tamoxifen Versus Toremifene in CYP2D6 IM/PM of Premenopausal Patients With ER-positive Early Breast Cancer

Role: collaborator

NCT02857153Not ApplicableUnknown

Effect of High vs. Low MAP Levels on Clinical Outcomes in Elderly Patients During Noncardiothoracic Surgery

Role: collaborator

All 12 trials loaded